The competition is fierce! Musk once said that "Tirzepatide", which is more effective than semaglutide, will be launched in China. Who will dominate the weight loss drug market in 2025?

① Today, Eli Lilly and Co announced the official launch of tirzepatide in China, covering both type 2 diabetes and weight loss, and it is already available on some online platforms; ② Musk has claimed that tirzepatide is better than semaglutide, while the market is more focused on the pricing of tirzepatide and whether it will be included in medical insurance; ③ The competition in the GLP-1 sector will become even more intense in 2025, with Jiangsu Hengrui Pharmaceuticals, INNOVENT BIO, and Gan & Lee Pharmaceuticals receiving widespread attention.

cls.cnJan 2 16:20

Shengnuo Bio (688117.SH): The project for Teirbo peptide Active Pharmaceutical Ingredient and formulation is currently in the pharmaceutical research stage.

Gelonghui reported on December 26 that Shengnuo Bio (688117.SH) stated on the investor interaction platform that the Active Pharmaceutical Ingredient and injection project for Semaglutide is currently in the pharmaceutical research stage, and the Active Pharmaceutical Ingredient for Semaglutide has been filed with the USA FDA. The project for the Active Pharmaceutical Ingredient and formulation of Teriparatide is also currently in the pharmaceutical research stage.

Gelonghui FinanceDec 26, 2024 18:02

Shengnuo Biotechnology (688117.SH): Lepu Medical Technology has cumulatively reduced its shareholding by 0.7912%.

On December 26, Gelonghui reported that Shengnuo Biology (688117.SH) announced that the company recently received a notification letter from Lepu Medical Technology regarding the results of shareholding reduction. As of the date of this announcement, Lepu Medical Technology has cumulatively reduced its shareholding by 889,445 shares through centralized bidding, accounting for 0.7912% of the company's total share capital. After the reduction, Lepu Medical Technology holds 5,272,000 shares of the company, accounting for 4.6896% of the company's total share capital, and this shareholding reduction plan has reached its expiration.

Gelonghui FinanceDec 26, 2024 16:46

Concept mining | Simgeglutide weight loss drug officially launched in China, multiple e-commerce platforms have gone online

The market has broad prospects

Gelonghui FinanceNov 17, 2024 14:35

Shengnuo Biology (688117): Rapid growth in Q3 performance, substantial order landing to boost medium and long-term development.

Q3 performance grew rapidly, with the three core sub-businesses showing overall stable development in 2024 Q1-3. The company achieved revenue of 0.338 billion yuan, a year-on-year increase of 16.00%; net income attributable to shareholders was 56.95 million yuan, a year-on-year increase of 63.66.

Open Source SecuritiesOct 31, 2024 18:33

Shengnuo Biology (688117): A pioneer in the peptide field, overseas layout to create long-term growth space.

The company released the Q3 financial report for 2024, with a revenue of 0.139 billion yuan, an increase of 18.32% year-on-year, and a net income attributable to non-controlling interests of 34.53 million yuan, an increase of 144.80% year-on-year. Revenue for the first three quarters of 2024 reached 3 billion yuan.

Guosheng SecuritiesOct 31, 2024 00:00